PharmacoEconomics

, Volume 11, Issue 1, pp 32–47 | Cite as

Measuring Quality of Life in Patients with Schizophrenia

  • A. George Awad
  • Lakshmi N.P. Voruganti
  • Ronald J. Heslegrave
Review Article Measuring Quality of Life in Schizophrenia

Abstract

Summary

Schizophrenia is a chronic disabling illness that affects about 1 % of the population. It is a heterogenous disorder with variable aetiological. prognostic and treatment response patterns. Its course is generally long term, with acute psychotic exacerbations that may require hospitalisation. The cornerstone of clinical management is the use of antipsychotic (neuroleptic) medications. Although these are effective, they can cause adverse effects that may impact negatively on the functional status of the individual.

Early studies of quality of life in schizophrenia were mainly concerned with the development of techniques to identify patients’ needs in the community. Difficulties encountered in these studies included: lack of agreement on definition of quality of life: lack of appropriate integrative conceptual models; concerns about reliability of patients’ self-reports about their quality of life; and the lack of standardised quality-of-life measures appropriate for schizophrenia.

A number of disease-specific or generic scales have subsequently been used for measurement of quality of life in schizophrenia. The list of disease-specific scales is extensive: unfortunately, many of them were used only in a single study or their psychometric properties were not specified. Generic scales can be applied across various types and severity of illness, as well as in different health interventions across demographic and cultural groups.

Medication costs in schizophrenia represent only a small fraction of the total cost of the illness. However, pharmacoeconomic studies have attracted much interest as a result of the high cost of newly introduced medications and of concern about the limitations of antipsychotic medications, particularly their adverse effects, as exemplified by the reintroduction of c10zapine for the treatment of refractory schizophrenia. Few studies have combined quality-of-life measures with cost analysis in schizophrenia; a number of these have methodological shortcomings. Many studies are retrospective in nature, and in most the number and length of hospitalisations has been used as the parameter for cost analysis, which can introduce bias depending on the varying approaches to hospitalisation.

We conclude that the following factors are important in choosing or developing a quality-of-life measure for schizophrenia: quality of life is a multidimensional concept that has to be reflected in its measurement; the scale has to be appropriate for the purpose as well as the population studied: measurement has to include patients’ self-reports about their quality of life; measures should include only items that are relevant and expected to change; single-item global measures are useful only when combined with multidimensional measures; in developing new scales, psychometric properties have to be established as well as being field-tested.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Shur E. The epidemiology of schizophrenia. Br J Hosp Med 1988; 40: 38–45PubMedGoogle Scholar
  2. 2.
    Eaton WW. Update on the epidemiology of schizophrenia. Epidemiol Rev 1991; 13: 320–8PubMedGoogle Scholar
  3. 3.
    Jablensky A, Sartorius N, Emberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures: a World Health Organization ten-country study. Psychol Med 1992; Suppl.20: 1–97Google Scholar
  4. 4.
    Davies LM, Drummond MF. The economic burden of schizophrenia. Psychiatr Bull 1990; 14: 522–5CrossRefGoogle Scholar
  5. 5.
    Castle DJ, Wessely S, Murray RM. Sell and schizophrenia: effects of diagnostic stringency and associates with premorbid variables. BrJ Psychiatry 1993; 162: 658–64CrossRefGoogle Scholar
  6. 6.
    Mayer C, Kalterborn G, Naber D. Age of onset in schizophrenia: relations to psychopathology and gender. Br J Psychiatry 1993; 162: 665–71PubMedCrossRefGoogle Scholar
  7. 7.
    Loranger AW. Sell difference in age at onset of schizophrenia. Arch Gen Psychiatry 1984; 41: 157–61PubMedCrossRefGoogle Scholar
  8. 8.
    Goodpastor WA, Hare BK. Factors associated with multiple readmissions to an urban public psychiatric hospital. Hosp Community Psychiatry 1991; 42: 85–7PubMedGoogle Scholar
  9. 9.
    Pablo RY, Kadlac KE, Arboleda-Aorez J. The readmission of psychotic patients to a general hospital psychiatry unit. Gen Hosp Psychiatry 1986; 8: 190–7PubMedCrossRefGoogle Scholar
  10. 10.
    Awad AG, Voruganti LNP, Heslegrave RJ. The aims of antipsychotic medication: what are they and are they being achieved? CNS Drugs 1995; 4: 8–16CrossRefGoogle Scholar
  11. 11.
    Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993; 19: 609–18PubMedGoogle Scholar
  12. 12.
    Awad AG, Hogan TP, Voruganti LNP, et al. Patients’ subjective ellperiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 1995; 10 Suppl.3: 123–33PubMedGoogle Scholar
  13. 13.
    Campbell A, Converse PE, Rogers WL. Subjective measures of well-being. Am Psychology 1976; 31: 117–24CrossRefGoogle Scholar
  14. 14.
    Campbell A. The sense of well-being in America. New York: McGraw-Hill, 1981Google Scholar
  15. 15.
    McCall S. Human needs and the quality of life. In: Shea WR, King Farlow J, editors. Values and quality of life. New York: Science History Publications, 1976: 6–24Google Scholar
  16. 16.
    World Health Organization. The constitution of the World Health Organization. WHO Chronicle 1947; 1: 29Google Scholar
  17. 17.
    Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA 1994; 272: 619–26PubMedCrossRefGoogle Scholar
  18. 18.
    Lamb RH. The new asylums in the community. Arch Gen Psychiatry 1979; 36: 129–34PubMedCrossRefGoogle Scholar
  19. 19.
    Bachrach LL. Deinstitutionalization: an analytic review and sociological perspective. Rockville (MD): National Institute of Mental Health, 1976Google Scholar
  20. 20.
    Lehman A, Ward N, Linn L. Chronic mental patients: the quality of life issue. Am J Psychiatry 1982; 139: 1271–6PubMedGoogle Scholar
  21. 21.
    Lehman A. The well-being of chronic mental patients: assessing their quality of life. Arch Gen Psychiatry 1983; 40: 369–73PubMedCrossRefGoogle Scholar
  22. 22.
    Sullivan G, Wells K, Leake B. Quality of life of seriously mentally ill persons in Mississippi. Hosp Community Psychiatry 1991; 42: 752–4PubMedGoogle Scholar
  23. 23.
    Levitt AJ, Hogan TP, Bucosky CM. Quality of life in chronically mentally ill patients in day treatment. Psychol Med 1990; 20: 703–10PubMedCrossRefGoogle Scholar
  24. 24.
    Corten P, Mercier C, Pelc J. Subjective quality of life: clinical model for assessment of rehabilitation treatment in schizophrenia. Soc Psychiatry Psychiatr Epidemiol 1994; 29: 178–83PubMedGoogle Scholar
  25. 25.
    Lehman A, Possidente S, Hawker F. The quality of life of chronic patients in state hospital and in community residences. Hosp Community Psychiatry 1986; 37: 901–7PubMedGoogle Scholar
  26. 26.
    Meltzer HY, Burnett S, Bastani B, et al. Effects of Sill months of c10zapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990; 41: 892–7PubMedGoogle Scholar
  27. 27.
    Awad AG. Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp Community Psychiatry 1992; 43: 262–5PubMedGoogle Scholar
  28. 28.
    Awad AG. Quality of life issues in medicated schizophrenics: therapeutic and research implications. In: Shriqui C, Nasrallah H, editors. Contemporary issues in the treatment of schizophrenia. Washington: American Psychiatric Press, 1995: 735–47Google Scholar
  29. 29.
    Awad AG, Voruganti LNP, Heslegrave RJ. Preliminary validation of a conceptual model to assess quality of life in schizophrenia. Qual Life Res. In pressGoogle Scholar
  30. 30.
    Hogan TP, Awad HG, Eastwood MR. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative ability. Psychol Med 1983; 13: 177–83PubMedCrossRefGoogle Scholar
  31. 31.
    Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 1992; 22: 347–52PubMedCrossRefGoogle Scholar
  32. 32.
    Van Putten T, May PRA. Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 1978; 35: 477–80PubMedCrossRefGoogle Scholar
  33. 33.
    Van Putten T, May PRA, Marder S, et al. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981; 38: 187–90PubMedCrossRefGoogle Scholar
  34. 34.
    Naber D, Walther A, Kirshere T, et al. Subjective effects of neuroleptics predict compliance. In: Gaebel W, Awad AG, editors. Prediction of neuroleptic treatment outcome in schizophrenia: concepts and methods. Vienna: Springer Verlag, 1995: 111–22Google Scholar
  35. 35.
    Davidhizar ER. Can clients with schizophrenia describe feelings and beliefs about taking medications? J Adv Nurs 1985; 10: 469–73PubMedCrossRefGoogle Scholar
  36. 36.
    Glazer W, Sholomskas D, Williams D, et al. Chronic schizophrenics in the community: are they able to report their social adjustment? Am J Orthopsychiatry 1982; 52: 166–71PubMedCrossRefGoogle Scholar
  37. 37.
    Voruganti LPN. Quality of life measurement in schizophrenia: a study of the credibility of patients’ reports of self-rated quality of life [dissertation). Toronto: Institute of Medical Science, University of Toronto, 1996Google Scholar
  38. 38.
    Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 37: 217–32CrossRefGoogle Scholar
  39. 39.
    Lehman AF, Bums BJ. Severe mental illness in the community. In: Spilker B, editor. Quality of life assessments in clinical trials. New York: Raven Press, 1990: 357–66Google Scholar
  40. 40.
    Pathek DS, Pleil AM, Funderburk FR. Quality of life and outcome assessment techniques — a resource guide. Kalamazoo, Michigan: Pharmacia Upjohn Publications, 1995Google Scholar
  41. 41.
    Stein LI, Test MA. Alternative to mental health treatment: I. conceptual model, treatment program and clinical evaluation. Arch Gen Psychiatry 1980; 37: 392–97PubMedCrossRefGoogle Scholar
  42. 42.
    Maim U, May PRA, Deneker SJ. Evaluation of the quality of life of the schizophrenic outpatient: a checklist. Schizophr Bull 1981; 7: 477–87Google Scholar
  43. 43.
    Baker F, Intagliata J. Quality of life in the evaluation of community support systems. Eval Program Plann 1982; 5: 69–79PubMedCrossRefGoogle Scholar
  44. 44.
    Bigelow DA, Brodsky G, Steward L, et al. The concept and measurement of quality of life as a dependent variable in evaluation of mental health services. In: Stahler GJ, Tash WR, editors. Innovative approaches to mental heahh evaluation. New York: Academic Press, 1982: 345–66Google Scholar
  45. 45.
    Lehman AF. Quality of life tool kit. Cambridge (MA): The Evaluation Center, 1995Google Scholar
  46. 46.
    Rosen A, Pavlovic H, Parker G. The life skills profile: a measure assessing function and disability in schizophrenia. Schizophr Bull 1989; 15: 325–34PubMedGoogle Scholar
  47. 47.
    Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit symptoms. Schizophr Bull 1984; 10: 388–98PubMedGoogle Scholar
  48. 48.
    Hurry J, Stuart E, Bebbington P, et al. Socio-demographic associations with social disablement in a community sample. Soc Psychiatry 1983; 18: 113–21PubMedCrossRefGoogle Scholar
  49. 49.
    Stuart E, Wykes T. Assessment schedules for chronic psychiatric patients. Psychol Med 1987; 17: 485–93CrossRefGoogle Scholar
  50. 50.
    Becker M, Diamond R, Sainfon F. A new patient focused index for measuring quality of life in persons with severe and persisteol meOlal illness. Qual Life Res 1993; 2: 239–51PubMedCrossRefGoogle Scholar
  51. 51.
    McDowell I, Newell C. Measuring health: a guide to rating scales and questionnaires. New York: Oxford University Press, 1987Google Scholar
  52. 52.
    Endicoll J, Spitzer RL, Fleiss JL, et al. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33: 766–71CrossRefGoogle Scholar
  53. 53.
    Diagnostic and Statistical Manual of Mental Disorders. 4th rev ed. Washington: American Psychiatric Association, 1994Google Scholar
  54. 54.
    Bergner M, Bobbit RA, Caner WB, et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787–805PubMedCrossRefGoogle Scholar
  55. 55.
    Ware Jr JE. The SF-36 health survey in quality of life and pharmacoeconomics in clinical trials. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincoll-Raven, 1996: 337–45Google Scholar
  56. 56.
    McHorney CA, Ware Jr JE, Lu R, et al. The MOS 36-item Shon-Form health survey (SF-36): III, tests of data quality scaling assumptions and reliability across diverse patient groups. Med Care 1994; 32: 40–66PubMedCrossRefGoogle Scholar
  57. 57.
    Chambers LW. The McMaster heahh index questionnaire. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven, 1996: 267–79Google Scholar
  58. 58.
    Voruganti LNP, Heslegrave RJ, Awad AG. Sickness Impact Profile (SIP) as a measure of patients’ quality of life (QOLl in clinical trials involving antipsychotic drugs. 45th Annual Meeting of the American College of Neuropsychopharmacology; 1995 December 11-15; San Juan, Pueno RicoGoogle Scholar
  59. 59.
    Kozma A, Stones M. Social desirability in measures of subjective well-being: a systematic evaluation. J Gerontol 1987; 42: 56–9PubMedGoogle Scholar
  60. 60.
    Revicki DA, Luce BR, Weschler JM, et al. Cost-effectiveness of clozapine for treatmeOl-resistant schizophrenic patients. Hosp Community Psychiatry 1990; 41: 850–4PubMedGoogle Scholar
  61. 61.
    Revicki DA, Luce BR, Weschler JM, et al. Clozapine’s costbenefits Icorrespondencel. Hosp Community Psychiatry 1991; 42: 93–4Google Scholar
  62. 62.
    Honigfeld G, Patin J. A two-year clinical and economic follow up of patients on clozapine. Hosp Community Psychiatry 1990; 41: 881–5Google Scholar
  63. 63.
    Reid WH, Mason M, Toprac M. Savings in hospital bed-days related to treatment with c1ozapine. Hosp Community Psychialry 1994; 45: 261–4Google Scholar
  64. 64.
    Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatmeOl of neuroleptic-resistant schizophrenics: impact on risk-benefit assessment. Am J Psychialry 1995; 152: 183–90Google Scholar
  65. 65.
    Addington DE, Jones B, Bloom D, et al. Reduction of hospital days in chronic SChizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993; 15: 917–26PubMedGoogle Scholar
  66. 66.
    Lindstrom E, von Knorring L, Eberhard G. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995; 17: 402–12PubMedCrossRefGoogle Scholar
  67. 67.
    Awad AG. Methodological and design issues in c1inicallrials of new neuroleptics — an overview. Br J Psychiatry 1993; 163 Suppl.22: 51–7Google Scholar
  68. 68.
    Revicki DA, Luce BR. Methods of pharmacoeconomic evaluation of new medicallrealrneOlS in psychiatry. Psychopharmacol Bull 1995; 31: 57–65PubMedGoogle Scholar
  69. 69.
    Data JL, Willke RJ, Barnes JR, et al. Re-engineering drug developmeol: integrating pharmacoeconomic research into the drug development process. Psychopharmacol Bull 1995; 31: 67–73PubMedGoogle Scholar
  70. 70.
    Finon A, Benfield P. Clozapine: an appraisal of its pharmacoeconomic benefits in the Ireatment of schizophrenia. Pharmacoeconomics 1993; 4: 131–56CrossRefGoogle Scholar
  71. 71.
    Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals in Canada. 1st ed. Ottawa: CCOHTA, 1994Google Scholar
  72. 72.
    Ministry of Health, Ontario, Canada. Ontario guidelines for economic analysis of pharmaceutical products. Toronto, Ontario: 1994Google Scholar
  73. 73.
    Detsky AS. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. Pharmacoeconomics 1993; 3: 354–61PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  • A. George Awad
    • 1
    • 2
  • Lakshmi N.P. Voruganti
    • 3
  • Ronald J. Heslegrave
    • 1
    • 4
  1. 1.Department of PsychiatryUniversity of TorontoTorontoCanada
  2. 2.The Clarke Institute of PsychiatryTorontoCanada
  3. 3.Victoria Hospital, University of Western OntarioLondonCanada
  4. 4.The Wellesley HospitalTorontoCanada

Personalised recommendations